S
ince varicella virus vaccine live became available in the United States in 1995, more than 55 million doses have been distributed. 1 Mild reactions at the injection site and localized rash may be associated with vaccination, 2 but serious adverse events are rare. Disseminated varicella-zoster virus (VZV) infections after vaccination have been reported in patients with underlying immunodeficiencies, including natural killer T cell defects, 3, 4 or with acquired immunodeficiency caused by HIV, 5 bone marrow transplant, 6 or other conditions. 1, 7 Localized rash is the most common adverse event reported in patients receiving the varicella virus vaccine live. Previously undiagnosed immunodeficiencies that were revealed after severe vaccine reactions have been reported in patients receiving live vaccines. 5, 8 The Vaccine Adverse Events Reporting System is a passive surveillance system administered by the Centers for Disease Control and Prevention and the US Food and Drug Administration that tracks all reported adverse events temporally related to vaccination. We describe a case of a woman who presented with a diffuse pruritic rash 17 days after receiving the varicella virus vaccine live. This reaction is unique because it occurred in a patient with no known immunocompromise.
Physicians must be aware of these potential adverse effects when recommending or administering vaccines to their patients. 
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